WHAT ARE THE EFFECTS OF THIS DRUG?
↑ 4.18 pounds average over 52 weeks with dose of 4 mg per day when Rosiglitazone is given alone (27)
↑ 5.5 pounds in 26 weeks 8mg/day contribution by Rosiglitazone (Avandia) in combination with sulfonylurea (e.g. Glimepiride) (183)
↑ 0.79 pound average in 12 weeks with dose of 2 mg per day when Rosiglitazone given alone (181)
↑ 0.4 pound average in 12 weeks with dose of 1 mg per day when Rosiglitazone given alone (181)
↑ Weight gain is fat and water for Rosiglitazone (25 and 27)
↑ 4.4 pounds in 4 months with both the 4 and 8 mg per day doses for Rosiglitazone when given alone (27)
↑ 6.38 pounds average over 52 weeks with dose of 8 mg per day when Rosiglitazone given alone (27)
↑ 5.72 pounds average over 52 weeks with dose of 8 mg per day when Rosiglitazone given alone (183)
↑ In combination Rosiglitazone with sulfonylurea (e.g. Glimepiride) weight gain greater than expected for combination (27)
↑ 4.18 to 6.16 pounds in 1year (27) for Rosiglitazone when given alone
* FDA Alert: Thiazolidinediones, including Rosiglitazone, can cause or exacerbate congestive heart failure (CHF) in some patients.
* FDA Alert: A meta-analysis of 52 clinical trials (mean duration, 6 months ; 16,995 total patients), most of which compared rosiglitazone with placebo, showed rosiglitazone to be associated with a statistically significant increased risk of myocardial infarction (MI). Three other trials (mean duration, 46 months; 14,067 total patients) comparing rosiglitazone with some other approved oral antidiabetic agents or placebo showed a statistically nonsignificant increased risk of MI and a statistically nonsignificant decreased risk of death. There have been no clinical trials directly comparing the cardiovascular risk of rosiglitazone and pioglitazone, another thiazolidinedione, but in a separate trial, pioglitazone (when compared with placebo) did not show an increased risk of MI or death.
Generic Name: Rosiglitazone &
Glimepiride